StockData

DocGo vs GeneDx

DCGO and WGS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DCGO and WGS compare

GeneDx is the larger company, worth 84 times as much as DocGo ($1.5B against $18.1M).

GeneDx grew revenue faster over the last twelve months (25.4% versus −32.4% for DocGo).

GeneDx keeps more of each dollar of sales as profit, with a net margin of −23.4% compared with −65.3% at DocGo.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDCGOWGS
Size and price
Market cap$18.1M$1.5B
Share price$0.183$51.02
Change, 1 year−82.9%−60.9%
Change, 5 years−97.6%−77.6%
Beta (5Y)2.220.82
Employees3,6001,300
StockData Score
Total score66
Valuation score3 (better)0
Growth score03 (better)
Performance score01 (better)
Health score3 (better)2
Dividend score00
Valuation
P/S0.1× (better)3.3×
P/B0.2× (better)6.2×
FCF yield−143%−5.0% (better)
Fair value$3.10$32.23
Margin of safety94.1% (better)−58.3%
Growth
Revenue growth (TTM)−32.4%25.4% (better)
Revenue growth, 5Y average27.9% (better)19.0%
Net income growth (TTM)–−7665%
EPS growth (TTM)–−18300%
Profitability
Gross margin–69.4%
Operating margin−62.2%−20.3% (better)
Net margin−65.3%−23.4% (better)
FCF margin−8.8% (better)−16.7%
Return on equity−92.4%−40.8% (better)
Return on invested capital−101%−36.2% (better)
Financial health
Debt / equity0.00 (better)0.40
Current ratio1.663.30 (better)
Altman Z-score−2.840.36 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions38.5%107%
Held by insiders9.8%–
Insider net buying, 12 months−$15.3K$91.2M (better)
Short interest, % of float2.4%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.